Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04020276
Recruitment Status : Recruiting
First Posted : July 16, 2019
Last Update Posted : September 14, 2022
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:

Stereotactic Body Radiation Therapy (SBRT) is a noninvasive local therapy with proven efficacy in a number of solid tumor types. However, colorectal cancer (CRC) liver metastases have been shown to be particularly resistant to SBRT, and often are found to have significantly worse rates of control compared with other histologies. Higher SBRT dose was recently shown to improve local control in CRC pulmonary metastases, however, increasing dose delivery with SBRT has been limited based on the risk of toxicity to adjacent structures, and the ability to visualize them during treatment. This is particularly relevant in treating liver tumors, as tumor and small bowel movement can often make tumor targeting and organs-at-risk (OAR) avoidance especially difficult. MRI-guided SBRT for liver tumors is both safe and feasible and offers an as yet unprecedented opportunity to achieve the highest possible safe dose to liver tumors.

The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided SBRT treatment of bowel and liver metastases, respectively.

Eligible participants will be on study for up to 12 months.

Condition or disease Intervention/treatment Phase
Liver Metastases Stereotactic Body Radiation Therapy MRI-guided Treatment Radiation: SBRT Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Phase IA: 4+4 dose-escalation design - patients will be treated to a maximum tolerated dose using MRI-guided SBRT with real time adaptation.

Phase IB: Confirmatory expansion cohort in patients with liver metastases from colorectal cancer.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IA/IB Study of OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
Actual Study Start Date : November 4, 2019
Estimated Primary Completion Date : February 2025
Estimated Study Completion Date : February 2025

Arm Intervention/treatment
Experimental: MRI-Guided SBRT Dose Escalation

Treatment on MRI Linac with SBRT in 5 fractions with adaptive planning, maximum dose 80 Gy

Dose Escalation Bowel Pathway, V34 < 0.5cc Dose Escalation Liver Pathway, 700 cc < 16 Gy

Subsequent Phase 1B: CRC only for Safety and Local Control, dosage informed by Phase 1A

Radiation: SBRT
Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB

Primary Outcome Measures :
  1. Number of Participants with Acute Dose Limiting Toxicity (DLT) [ Time Frame: Up to 4 weeks ]

    Dose limiting toxicity (DLT) will be defined as grade 3 or greater* non-hematologic toxicity attributable to radiation therapy, and occurring within 4 weeks after the completion of SBRT.

    *With the exception of liver function tests, which are allowed up to and including grade 3

Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Up to 5 years ]
    Progression-free survival (PFS) will be defined as the difference (in months) between the date of study enrollment and the date of disease progression or death due to any cause

  2. Overall Survival (OS) [ Time Frame: Up to 5 years ]
    Overall survival (OS) will be defined as the difference (in months) between the date of study enrollment to the date death due to any cause.

  3. Local Control Rates [ Time Frame: up to 1 year ]
    Point estimates along with the exact 95% confidence interval will be computed for the local control rates

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • For Phase IA trial, have a diagnosis of histologically confirmed or clinically suspected metastatic cancer to the liver; for Phase IB trial have have a diagnosis of histologically confirmed or clinically suspected metastatic CRC to the liver.
  • Participant must be a candidate for SBRT to at least one intrahepatic lesion but no more than 6 intrahepatic lesions.
  • Participant must be a candidate for treatment on the ViewRay treatment unit. Must be screened to rule out implants and devices that are not MRI compatible.
  • Be willing and able to provide written informed consent.
  • Participants may be therapy-naïve or have had prior systemic therapy up to two weeks prior to study entry.
  • No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet all of the following to be eligible:

    • At least 28 days from prior definitive treatment of their CNS disease by surgical resection, SBRT or Whole Brain Radiation Therapy (WBRT) at the time of registration
    • AND asymptomatic and off systemic corticosteroids and/or enzyme-inducing antiepileptic medications for brain metastases for >14 days prior to registration.
  • Demonstrate adequate organ function as defined in the following table; all screening labs should be performed within 28 days of SBRT treatment initiation.

    • Platelet count greater than or equal to 50000 /µL
    • Absolute Neutrophil Count (ANC) greater than or equal to 1000 /µL
    • Hemoglobin (Hgb) greater than or equal to 8 g/dL or greater than or equal to 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
    • Serum creatinine OR measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) Creatinine/Calculated creatinine clearance (CrCl) greater than or equal to 30 mL/min for subject with creatinine levels greater than 1.5 X institutional upper limit of normal (ULN)
    • Bilirubin greater than or equal to 1. 5 × ULN OR direct bilirubin greater than or equal to ULN for participants with total bilirubin levels greater than 1.5 ULN
    • Aspartate aminotransferase (AST) and ALT (SGPT) greater than or equal to 5 × ULN
    • International Normalized Ratio (INR) or Prothrombin Time (PT) greater than or equal to 1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
    • Activated Partial Thromboplastin Time (aPTT) greater than or equal to 1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • For participants enrolled on the liver dose escalation arm, screening labs must be consistent with Child Pugh class A unless therapeutic anticoagulation places them in Child Pugh B. In that case, trial entry or exclusion will be at the discretion of the treating physician.
  • Have a performance status of 2 or less on the Eastern Cooperative Oncology Group (ECOG) performance scale.
  • Life expectancy of > 12 weeks.
  • Women of childbearing potential (WOCP) should have a negative urine or serum pregnancy test prior to initiation of radiation therapy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • WOCP must not be pregnant or breast-feeding.
  • WOCP must be willing to use an effective method of birth control such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the duration of the radiotherapy and 60 days thereafter.

NOTE: A person of childbearing potential is anyone (regardless of sexual orientation, gender identity, having undergone a tubal ligation, or remaining celibate by choice) who was born with a uterus and at least one ovary and meets both of the following criteria:

  • Is post-menarcheal (i.e., has had at least one prior menses)
  • Has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the initiation of SBRT.
  • History of a second invasive cancer in the last 3 years (except for appropriately treated low-risk prostate cancer, treated non-melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast appropriately treated in situ/early stage cervical/endometrial cancer.
  • Has an active infection requiring systemic therapy.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with follow up scans or visits.
  • Has a primary tumor histology of germ cell tumor, leukemia, or lymphoma.
  • Has a primary liver cancer such as cholangiocarcinoma or hepatocellular carcinoma.
  • Has had prior radiation therapy that significantly overlaps with the liver.
  • Has a diagnosis of Crohn's disease, ulcerative colitis, or scleroderma.
  • Participants with Gilbert's disease or other primary disorders of bilirubin metabolism will not be allowed on the trial.
  • For participants in the liver dose escalation arm only, has pre-existing liver disease such that patients are classified as Child Pugh B or worse. If the participant is anti-coagulated such that their INR places them in the CP-B classification, exclusion or inclusion will be at the discretion of the treating physician.
  • Pregnancy or women of childbearing potential and men who are sexually active and refuse to use medically acceptable forms of contraception.
  • Participants with implanted hardware that would preclude MRIs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04020276

Layout table for location contacts
Contact: Cancer Connect 800-622-8922

Layout table for location information
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Contact: Cancer Connect    800-622-8922   
Sponsors and Collaborators
University of Wisconsin, Madison
Layout table for investigator information
Principal Investigator: Michael Bassetti, MD, PhD University of Wisconsin, Madison
Additional Information:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison Identifier: NCT04020276    
Other Study ID Numbers: UW18110
SMPH/HUMAN ONCOLOGY/HUMAN ONCO ( Other Identifier: UW Madison )
A533300 ( Other Identifier: UW Madison )
2019-0373 ( Other Identifier: HS IRB )
NCI-2019-04726 ( Registry Identifier: NCI Trial ID )
Protocol Version 7/20/2021 ( Other Identifier: UW Madison )
First Posted: July 16, 2019    Key Record Dates
Last Update Posted: September 14, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases